4
Changes in Ownership
Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000104
Chief Executive Officer sold 25,000 shares at an average $83.62 ($2,090,593)
- Chief Executive Officer acquired 25,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Klein Lawrence Otto Chief Executive Officer | 2026-10-01 | Option exercise 10b5-1 | +25,000 | $7.80 | $195,000 | 948,128 | D |
| Klein Lawrence Otto Chief Executive Officer | 2026-10-01 | Sale 10b5-1 | −16,246 | $83.40 | $1,354,882 | 931,882 | D |
| Klein Lawrence Otto Chief Executive Officer | 2026-10-01 | Sale 10b5-1 | −8,554 | $84.03 | $718,755 | 923,328 | D |
| Klein Lawrence Otto Chief Executive Officer | 2026-10-01 | Sale 10b5-1 | −200 | $84.78 | $16,956 | 923,128 | D |
| Derivatives | |||||||
| Klein Lawrence Otto Chief Executive Officer | 2026-10-01 | Option exercise · Employee Warrant (right to buy) 10b5-1 | −25,000 | 1,528,513 | D | ||
| Open-market sales · 25,000 sh · avg $83.62 · $2,090,593 | |||||||
Loading xslF345X06/form4.xml…